Search results for DDAH1 antibody

HRP Anti-DDAH1 antibody [EPR13922], Abcam, AB306234

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE Anti-DDAH1 antibody [EPR13922], Abcam, AB306232

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) Antibody, Abbexa, abx125747

DDAH1 Antibody is a Rabbit Polyclonal against DDAH1.

DDAH1 antibody [C2C3], C-term, Genetex, GTX104660

Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) Antibody, Abbexa, abx031779

DDAH1 plays a role in nitric oxide generation by regulating cellular concentrations of methylarginines, which in turn inhibit nitric oxide synthase activity.

Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) Antibody, Abbexa, abx214619

DDAH1 Antibody is a Rabbit Polyclonal against DDAH1.

APC Anti-DDAH1 antibody [EPR13922], Abcam, AB306233

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) Antibody, Abbexa, abx172123

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) Antibody is a Mouse Monoclonal antibody against Dimethylarginine Dimethylaminohydrolase 1 (DDAH1).

Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) Antibody, Abbexa, abx214218

DDAH1 Antibody is a Rabbit Polyclonal against DDAH1.

DDAH1 Antibody (YA2661)(PBS only), MedChemexpress, HY-P82916A

DDAH1 Antibody (YA2661) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DDAH1.